Advertisement Quick-Med and Avery Dennison sign development agreement - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

Quick-Med and Avery Dennison sign development agreement

Quick-Med Technologies and Avery Dennison have entered into a joint development and exclusive option agreement to collaborate in applying Quick-Med's Nimbus technology to adhesives for medical device and industrial applications.

According to Quick-Med Technologies, Nimbus is a next-generation antimicrobial technology that is non-leaching, non-toxic, long-lasting and not blocked by organics such as blood, urine and perspiration.

Ladd Greeno, CEO of Quick-Med Technologies, said: “We are excited to team with Avery Dennison to incorporate our advanced Nimbus technology in adhesives. This collaboration will leverage Nimbus technology to a next generation of antimicrobial adhesives to address growing infection concerns.”